^
Association details:
Biomarker:No biomarker
Cancer:Mantle Cell Lymphoma
Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/24/2022
Excerpt:
REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with...Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies...
Evidence Level:
Sensitive: A1 - Approval
Published date:
06/14/2007
Excerpt:
Revlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Mantle cell lymphoma: Other recommended regimens...Lenalidomide
Evidence Level:
Sensitive: B - Late Trials
Title:

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

Published date:
12/22/2020
Excerpt:
At a median follow-up of 38 months after randomisation (IQR 24–50), 3-year progression-free survival was 80% (95% CI 70–87) in the lenalidomide group versus 64% (53–73) in the observation group (log-rank test p=0·012; hazard ratio 0·51, 95% CI 0·30–0·87)...lenalidomide after autologous HSCT improved progression-free survival in patients with mantle cell lymphoma, highlighting the role of maintenance in mantle cell lymphoma.
DOI:
10.1016/S2352-3026(20)30358-6
Trial ID: